SCOPUS 정보 검색 플랫폼

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis

(6) Gentilini, Fabiana a Levi, Anna a Federico, Vincenzo a Russo, Eleonora a Foà, Robin a Petrucci, Maria Teresa a

a SAPIENZA UNIVERSITY OF ROME (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALBUMIN; BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCIUM; CIPROFLOXACIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; INSULIN; SYNDECAN 1;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL COLONIZATION; BONE DENSITY; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG SAFETY; FRACTURE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOPOROSIS; PANCREAS INSUFFICIENCY; PARAPROTEINEMIA; PLASMACYTOSIS; PSEUDOMONAS AERUGINOSA; UNSPECIFIED SIDE EFFECT; URINALYSIS;

EID: 84875949589 PISSN: None EISSN: 20353006 Source Type: Journal
DOI: 10.4084/MJHID.2012.035 Document Type: Article

Times cited : (4)

References (13)

1
- 0037973279
- A phase 2 study of bortezomib in relapsed, refractory myeloma
- PMid:12826635
- Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. http://dx.doi.org/10.1056/NEJMoa030288 PMid:12826635
- (2003) N Engl J Med. , vol.348 , pp. 2609-2617
- Richardson, P.G.¹ Barlogie, B.² Berenson, J.³

2
- 5644250621
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
- PMid:15461622
- Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004; 127: 165-172. http://dx.doi.org/10.1111/j.1365-2141.2004.05188.x PMid:15461622
- (2004) Br J Haematol. , vol.127 , pp. 165-172
- Jagannath, S.¹ Barlogie, B.² Berenson, J.³

3
- 20444433230
- Bortezomib or high-dose dexamethasone for relapsed myeloma
- PMid:15958804
- Richardson PG, Sonneveld P, Schuster MS, et al. Bortezomib or high-dose dexamethasone for relapsed myeloma. N Engl J Med. 2005; 352:2487-2498. http://dx.doi.org/10.1056/NEJMoa043445 PMid:15958804
- (2005) N Engl J Med. , vol.352 , pp. 2487-2498
- Richardson, P.G.¹ Sonneveld, P.² Schuster, M.S.³

4
- 74949121208
- VMP is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study
- PMid:19858394
- Dimopoulos MA, Richardson PG, Schlag R, et al. VMP is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27:6086-93. http://dx.doi.org/10.1200/JCO.2009.22.2232 PMid:19858394
- (2009) J Clin Oncol. , vol.27 , pp. 6086-6093
- Dimopoulos, M.A.¹ Richardson, P.G.² Schlag, R.³

5
- 78650303860
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85. http://dx.doi.org/10.1016/S0140-6736(10)61424-9
- (2010) Lancet , vol.376 , pp. 2075-2085
- Cavo, M.¹ Tacchetti, P.² Patriarca, F.³

6
- 56449106917
- Cystic fibrosis-related dyslipidemia
- Alves CAD, Lima DS. Cystic fibrosis-related dyslipidemia, J Bras Pneumol. 2008;34:829-837. http://dx.doi.org/10.1590/S1806-37132008001000012
- (2008) J Bras Pneumol , vol.34 , pp. 829-837
- Alves, C.A.D.¹ Lima, D.S.²

7
- 84875998239
- Cystic Fibrosis-Related Diabetes: From CFTR Dysfunction to Oxidative Stress
- Clin Biochem Rev Vol 30 November
- Ntimbane T, Comte B, Mailhot G, et al. Cystic Fibrosis-Related Diabetes: From CFTR Dysfunction to Oxidative Stress, Clin Biochem Rev Vol 30 November 2008.
- (2008)
- Ntimbane, T.¹ Comte, B.² Mailhot, G.³

8
- 53949092520
- Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients
- PMid:18801200 PMCid:2567975
- Papaioannou A, Kennedy CC, Freitag A et al. Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients. BMC Musculoskeletal Disorders 2008, 9:125. http://dx.doi.org/10.1186/1471-2474-9-125 PMid:18801200 PMCid:2567975
- (2008) BMC Musculoskeletal Disorders , vol.9 , pp. 125
- Papaioannou, A.¹ Kennedy, C.C.² Freitag, A.³

9
- 84988241358
- International uniform response criteria for multiple myeloma
- PMid:16855634
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma, Leukemia. 2006;20:1467-73. http://dx.doi.org/10.1038/sj.leu.2404284 PMid:16855634
- (2006) Leukemia , vol.20 , pp. 1467-73
- Durie, B.G.¹ Harousseau, J.L.² Miguel, J.S.³

10
- 68649100255
- The proteostasis boundary in misfolding diseases of membrane traffic
- PMid:19708088 PMCid:2805282
- Hutt DM, Powers ET, Balch WE. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett. 2009;583:2639-46. http://dx.doi.org/10.1016/j.febslet.2009.07.014 PMid:19708088 PMCid:2805282
- (2009) FEBS Lett. , vol.583 , pp. 2639-2646
- Hutt, D.M.¹ Powers, E.T.² Balch, W.E.³

11
- 78049488759
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
- PMid:20823406
- Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621-9. http://dx.doi.org/10.1200/JCO.2009.27.9158 PMid:20823406
- (2010) J Clin Oncol. , vol.28 , pp. 4621-4629
- Harousseau, J.L.¹ Attal, M.² Avet-Loiseau, H.³

12
- 42249104882
- Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up
- PMid:18371113
- Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br J Haematol 2008;141:512-516. http://dx.doi.org/10.1111/j.1365-2141.2008.06997.x PMid:18371113
- (2008) Br J Haematol , vol.141 , pp. 512-516
- Popat, R.¹ Oakervee, H.E.² Hallam, S.³

13
- 84876012690
- Cystic Fibrosis Foundation Patient Registry 2006 Annual data report to the center directors. Bethesda, Maryland
- Cystic Fibrosis Foundation Patient Registry 2006 Annual data report to the center directors. Bethesda, Maryland; 2007.
- (2007)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.